Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23731908 | 0.88 | KMT2A (0.54) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL8775304 | 0.84 | KMT2A (0.57) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL3494511 | 0.83 | KMT2A (0.55) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL4666968 | 0.83 | MEN1 (0.55) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL973673 | 0.83 | KMT2A (0.69) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL3589983 | 0.82 | KMT2A (0.51) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL436607 | 0.82 | TRPA1 (0.48) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL5450997 | 0.81 | MEN1 (0.56) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL29114074 | 0.79 | KMT2A (0.58) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL29270972 | 0.79 | ALDH1A1 (0.48) | KMT2AMEN1NPC1TDP1MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450352-B2 | Thiazole compounds and their use for inhibiting phosphodiesterase 4, TNF-α, and IL-4 | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20100094002-A1 | Thiazole Compound and Use Thereof | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-04-15 | — | — | US | disclosed |
| US-7655680-B2 | (E)-3-[2-(3,4-diethoxyphenyl)thiazole-4-yl]-1-(2-methoxyphenyl)propenone; inhibiting the activity of phosphodiesterase 4, the production of tumor necrosis factor alpha, and the production of interleukin 4; atopic dermatitis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20080039511-A1 | Thiazole Compound and Use Thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1748044-A1 | THIAZOLE COMPOUND AND USE THEREOF | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094002-A1 | Thiazole Compound and Use Thereof | PDE3B, IL4, PDE4A | KMT2A 4633/4885MEN1 1975/4885NPC1 3259/4885 |
| US-20080039511-A1 | Thiazole Compound and Use Thereof | PDE3B, PDE3A, PDE4A | KMT2A 3873/4885MEN1 2252/4885NPC1 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.